Overview
Shift Bioscience is a biotechnology company headquartered in Cambridge, United Kingdom, focused on developing therapeutics that target the underlying mechanisms of cellular aging. The company employs an AI-powered virtual cell platform combined with proprietary epigenetic aging clocks to identify and validate gene targets for cell rejuvenation across multiple age-driven diseases. Its pipeline includes SB101, an anti-fibrotic siRNA therapeutic for liver fibrosis and systemic sclerosis, and SB000, a gene therapy candidate for age-related sensory loss. Through its CLOCKWORK discovery platform, Shift aims to deliver the first drug pipeline validated for cellular age reversal in humans, addressing the root causes of aging-related morbidity and mortality.